| Literature DB >> 30405521 |
Laure Fernandez1, Raoul Huys2, Johann Issartel3, Jean-Philippe Azulay4, Alexandre Eusebio4,5.
Abstract
Patients with Parkinson's disease (PD) often have difficulties generating rhythmic movements, and also difficulties on movement adjustments to accuracy constraints. In the reciprocal aiming task, maintaining a high accuracy comes with the cost of diminished movement speed, whereas increasing movement speed disrupts end-point accuracy, a phenomenon well known as the speed-accuracy trade-off. The aim of this study was to examine how PD impacts speed-accuracy trade-off during rhythmic aiming movements by studying the structural kinematic movement organization and to determine the influence of dopamine replacement therapy on continuous movement speed and accuracy. Eighteen patients with advanced idiopathic Parkinson's disease performed a reciprocal aiming task, where the difficulty of the task was manipulated through target width. All patients were tested in two different sessions: ON-medication and OFF-medication state. A control group composed of healthy age-matched participants was also included in the study. The following variables were used for the analyses: Movement time, Error rate, effective target width, and Performance Index. Percentage of acceleration time and percentage of non-linearity were completed with kinematics patterns description using Rayleigh-Duffing model. Both groups traded off speed against accuracy as the constraints pertaining to the latter increased. The trade-off was more pronounced with the PD patients. Dopamine therapy allowed the PD patients to move faster, but at the cost of movement accuracy. Surprisingly, the structural kinematic organization did not differ across group nor across medication condition. These results suggest that PD patients, when involved in a reciprocal aiming task, are able to produce rhythmic movements. PD patients' overall slowing down seems to reflect a global adaptation to the disease in the absence of a structurally altered kinematic organization.Entities:
Keywords: dopamine; goal-directed movement; parkinson's disease; rhythmicity; speed-accuracy trade-off
Year: 2018 PMID: 30405521 PMCID: PMC6208126 DOI: 10.3389/fneur.2018.00897
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Methodological representation of reciprocal aiming task under low (upper left panel) and high (upper right panel) index of difficulty. Position, velocity and acceleration profiles are represented for two successive aiming cycles.
Demographic and drug details of PD Patients and controls.
| 1 | F | 56 | 10 | l-dopa 550 mg; entacapone 1,200 mg; pramipexole ER 2.10 mg; rasagiline 1 mg | 17 | 2 | 0 | 0 | 0 | 0 |
| 2 | F | 69 | 30 | l-dopa 350 mg; pramipexole 2.1 mg | 24 | 9 | 0 | 5 | 0 | 1 |
| 3 | F | 59 | 8 | l-dopa 700 mg; pramipexole ER 2.62 mg; entacapone 1,200 mg | 30 | 10 | 0 | 1 | 1 | 0 |
| 4 | M | 57 | 14 | l-dopa 1,000 mg; entacapone 800 mg; ropinirole ER 16 mg | 31 | 12 | 0 | 3 | 0 | 0 |
| 5 | M | 65 | 7 | l-dopa 1,300 mg; ropinirole ER 4 mg | 48 | 9 | 0 | 6 | 1 | 0 |
| 6 | F | 70 | 10 | l-dopa 600 mg | 21 | 5 | 0 | 1 | 0 | 0 |
| 7 | M | 69 | 11 | l-dopa 750 mg; rasagiline 1 mg | 18 | 6 | 0 | 7 | 1 | 0 |
| 8 | F | 65 | 11 | l-dopa 400 mg; entacapone 800 mg; ropinirole ER 10 mg | 25 | 14 | 2 | 2 | 0 | 0 |
| 9 | F | 68 | 6 | l-dopa 675 mg; rasagiline 1 mg | 36 | 23 | 0 | 0 | 0 | 1 |
| 10 | M | 46 | 6 | l-dopa 475 mg; entacapone 1,000 mg; ropinirole ER 24 mg; rasagiline 1 mg | 21 | 1 | 2 | 7 | 1 | 0 |
| 11 | M | 63 | 16 | l-dopa 900 mg; entacapone 1,000 mg; ropinirole ER 16 mg | 33 | 14 | 7 | 4 | 0 | 0 |
| 12 | F | 68 | 10 | l-dopa 625 mg; entacapone 1,000 mg; rotigotine 8 mg; rasagiline 1 mg | 26 | 15 | 0 | 6 | 0 | 0 |
| 13 | M | 41 | 5 | l-dopa 850; entacapone 1,200 mg; pramipexole ER 0.52 mg; rasagiline 1 mg | 31 | 1 | 0 | 7 | 1 | 0 |
| 14 | F | 56 | 8 | l-dopa 500 mg; ropinirole ER 6 mg; rasagiline 1 mg | 15 | 3 | 1 | 4 | 0 | 0 |
| 15 | F | 44 | 8 | l-dopa 675 mg; entacapone 1,200 mg | 23 | 3 | 2 | 4 | 1 | 0 |
| 16 | F | 56 | 22 | l-dopa 150 mg; entacapone 800 mg; amantadine 100 mg | 21 | 3 | 3 | 4 | 0 | 0 |
| 17 | M | 70 | 10 | l-dopa 750 mg; entacapone 1,200 mg; rasagiline 1 mg; pramipexole ER 1.05 mg | 10 | 0 | 3 | 3 | 0 | 0 |
| 18 | M | 59 | 21 | l-dopa 1,000 mg; entacapone 800 mg; bromocriptine 7.5 mg | 38 | 18 | 0 | 2 | 0 | 0 |
| 8M | Mean | 60.06 | 11.8 | 26 | 8.22 | 1.11 | 3.67 | 0.33 | 0.11 | |
| 10F | SD | 9.14 | 6.6 | 9.25 | 6.66 | 1.84 | 2.35 | 0.49 | 0.32 | |
| 5M | Mean | 59.39 | ||||||||
| 13F | 8.37 | |||||||||
UPDRS = Unified Parkinson's Disease Rating Scale motor.
Dyskinesia = Severity of dyskinesias assessed using the Marconi dyskinesia Scale.
Post action Tremor score for preferred hand.
Figure 2Each panel depicts one performance variable as a function of the Index of difficulty, Group, and session for the PD patients and control groups. In panel A-F Session 1 and Session 2 correspond to the ON and OFF conditions for the PD patients group, respectively. The vertical bars depict the standard deviation of the mean. Each panel represents the following performance variable: (A) Average movement time, (B) Average error rate percentage, (C) We/W ratio, (D) Percentage of Acceleration time, (E) Non-linearity percentage and (F) Index of Performance.
Results from the ANCOVA performed on MT, Error rate and We/W ratio to test the interaction of (i) Dopamine treatment and dyskinesia score (Marconi), and (ii) Dopamine treatment and tremor score post action.
| Dopa Session (ON/OFF) | 0.46/0.50 | 0.013 |
| AIMS Score | 1.46/0.23 | 0.041 |
| Session*AIMS | 1.82/0.19 | 0.051 |
| Dopa Session (ON/OFF) | 1.07/0.31 | 0.029 |
| Tremor score | 3.12/0.09 | 0.085 |
| Session*Tremor | 0.71/0.41 | 0.019 |
| Dopa Session (ON/OFF) | 0.79/0.381 | 0.022 |
| AIMS Score | 0.98/0.329 | 0.027 |
| Session*AIMS | 1.93/0.174 | 0.054 |
| Dopa Session (ON/OFF) | 3.33/0.07 | 0.077 |
| Tremor score | 0.16/0.70 | 0.004 |
| Session*Tremor | 7.98/0.01 | 0.183 |
| Dopa Session (ON/OFF) | 3.3/0.07 | 0.092 |
| AIMS Score | 0.07/0.79 | 0.002 |
| SessionAIMS | 0.29/0.59 | 0.008 |
| Dopa Session (ON/OFF) | 5.34/0.03 | 0.103 |
| Tremor score | 0.01/0.90 | 0.0002 |
| Session*Tremor | 14.63/0.001 | 0.281 |
Figure 3Normalized averaged Hooke portraits of the movements observed under the ON-medication session (upper panel) and OFF-medication session (lower panel) for the three ID for PD patients group. The black line represents the Hooke portraits experimental data and the red dotted line the Hooke portraits from the RD model.
Figure 4Normalized averaged Hooke portraits of the movements observed under the Session 1 (upper panel) and Session 2 (lower panel) for the three ID for control group. The black line represents the Hooke portraits experimental data and the red dotted line the Hooke portraits from the RD model.
Figure 5Coefficients of the RD model (normalized in space and time) as a function of the Index of Difficulty for both sessions for the PD patients group and the control group. Session 1 and Session 2 correspond, respectively, to the ON and OFF conditions for the PD patients group. The vertical bars depict the standard deviation of the mean. Linear and non-linear coefficients of position-dependent (conservative) terms are presented in (A,B), respectively, and linear and non-linear coefficients of the velocity-dependent terms are presented in (C,D), respectively.